Cardio Diagnostics Reports Q2 2026 Financial Results with Revenue Decline and Improved Net Loss

Cardio Diagnostics Holdings, Inc. reported its financial results for the quarter ended June 30, 2026, revealing a revenue of $5,360, a decline from $7,475 in the same period last year. For the first half of 2026, the company generated $8,040 in revenue, slightly down from $8,415 in the first half of 2025. The net loss for the second quarter was $1,501,468, an improvement from a loss of $1,683,199 in the prior year, while the loss for the six months ended June 30, 2026, was $3,289,626, compared to $3,318,263 in the same period of 2025. The decrease in net loss was attributed to reduced operating expenses, particularly in research and development and general administrative costs.

The company’s total operating expenses for the second quarter of 2026 were $1,503,507, down from $1,686,174 in the same quarter of 2025. This reduction was primarily due to lower general and administrative expenses, which decreased from $1,296,303 to $1,144,802. Despite the overall decrease in expenses, Cardio Diagnostics continues to invest in its growth, with research and development expenses remaining relatively stable at $162,929 for the second quarter of 2026 compared to $178,536 in the previous year.

In terms of operational developments, Cardio Diagnostics has made strides in expanding its market presence. The company has increased the number of provider organizations offering its tests, which include the Epi+Gen CHD and PrecisionCHD tests. Additionally, the company launched HeartRisk™, a cardiovascular disease risk intelligence platform, and is pursuing international market opportunities, including a partnership in India. The establishment of a new high-complexity CLIA lab has also been completed, allowing the company to process patient samples internally, which is expected to reduce costs.

As of June 30, 2026, Cardio Diagnostics had cash and cash equivalents totaling $5,586,697, an increase from $5,110,630 at the end of 2025. The company reported net cash used in operating activities of $2,904,576 for the first half of 2026, a slight decrease from $2,971,566 in the same period of 2025. Cash provided by financing activities increased to $3,491,128, driven by proceeds from the sale of common stock. The company continues to explore additional financing options to support its operations and growth strategy, particularly in light of the ongoing need for capital to fund its initiatives.

Looking ahead, Cardio Diagnostics anticipates that sales and partnership cycles will remain lengthy, and it is focused on expanding its product offerings and market reach. The company is actively pursuing reimbursement coverage for its tests and plans to enhance its sales and marketing efforts, particularly in new markets. However, it faces challenges related to maintaining its listing on the Nasdaq Capital Market, as recent regulatory changes could impact its market value and ability to raise capital.